XNCR
Price
$11.77
Change
-$0.05 (-0.42%)
Updated
Oct 3 closing price
Capitalization
839.47M
35 days until earnings call
ZBIO
Price
$21.76
Change
+$0.81 (+3.87%)
Updated
Oct 3 closing price
Capitalization
916.32M
36 days until earnings call
Interact to see
Advertisement

XNCR vs ZBIO

Header iconXNCR vs ZBIO Comparison
Open Charts XNCR vs ZBIOBanner chart's image
Xencor
Price$11.77
Change-$0.05 (-0.42%)
Volume$540.91K
Capitalization839.47M
Zenas Biopharma
Price$21.76
Change+$0.81 (+3.87%)
Volume$142.88K
Capitalization916.32M
XNCR vs ZBIO Comparison Chart in %
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
XNCR vs. ZBIO commentary
Oct 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is XNCR is a Buy and ZBIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 06, 2025
Stock price -- (XNCR: $11.77 vs. ZBIO: $21.76)
Brand notoriety: XNCR and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: XNCR: 57% vs. ZBIO: 64%
Market capitalization -- XNCR: $839.47M vs. ZBIO: $916.32M
XNCR [@Biotechnology] is valued at $839.47M. ZBIO’s [@Biotechnology] market capitalization is $916.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

XNCR’s FA Score shows that 1 FA rating(s) are green whileZBIO’s FA Score has 0 green FA rating(s).

  • XNCR’s FA Score: 1 green, 4 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, both XNCR and ZBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

XNCR’s TA Score shows that 4 TA indicator(s) are bullish while ZBIO’s TA Score has 4 bullish TA indicator(s).

  • XNCR’s TA Score: 4 bullish, 4 bearish.
  • ZBIO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both XNCR and ZBIO are a good buy in the short-term.

Price Growth

XNCR (@Biotechnology) experienced а +1.73% price change this week, while ZBIO (@Biotechnology) price change was +8.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

XNCR is expected to report earnings on Nov 10, 2025.

ZBIO is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZBIO($916M) has a higher market cap than XNCR($839M). ZBIO YTD gains are higher at: 165.690 vs. XNCR (-48.782). XNCR has higher annual earnings (EBITDA): -125.38M vs. ZBIO (-189M). XNCR has more cash in the bank: 444M vs. ZBIO (273M). ZBIO has less debt than XNCR: ZBIO (1.01M) vs XNCR (67.9M). XNCR has higher revenues than ZBIO: XNCR (147M) vs ZBIO (15M).
XNCRZBIOXNCR / ZBIO
Capitalization839M916M92%
EBITDA-125.38M-189M66%
Gain YTD-48.782165.690-29%
P/E RatioN/AN/A-
Revenue147M15M980%
Total Cash444M273M163%
Total Debt67.9M1.01M6,736%
FUNDAMENTALS RATINGS
XNCR vs ZBIO: Fundamental Ratings
XNCR
ZBIO
OUTLOOK RATING
1..100
3941
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4036
P/E GROWTH RATING
1..100
5100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZBIO's Valuation (38) in the null industry is somewhat better than the same rating for XNCR (85) in the Biotechnology industry. This means that ZBIO’s stock grew somewhat faster than XNCR’s over the last 12 months.

ZBIO's Profit vs Risk Rating (100) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that XNCR’s stock grew similarly to ZBIO’s over the last 12 months.

ZBIO's Price Growth Rating (36) in the null industry is in the same range as XNCR (40) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for ZBIO (100) in the null industry. This means that XNCR’s stock grew significantly faster than ZBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
XNCRZBIO
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
71%
Bullish Trend 6 days ago
90%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
71%
Aroon
ODDS (%)
Bullish Trend 3 days ago
61%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIDLX35.210.11
+0.31%
MFS International New Discovery R6
JFEIX41.410.10
+0.24%
JPMorgan Europe Dynamic L
DFESX18.110.04
+0.22%
DFA Emerging Markets Social Core Port
MNRGX47.450.03
+0.06%
Manor Growth
GGRCX17.20-0.06
-0.35%
Goldman Sachs Strategic Growth C

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with PYXS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then PYXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
+3.87%
PYXS - ZBIO
42%
Loosely correlated
+14.22%
CRNX - ZBIO
42%
Loosely correlated
-1.57%
NUVL - ZBIO
42%
Loosely correlated
+0.43%
REPL - ZBIO
41%
Loosely correlated
+1.72%
XNCR - ZBIO
41%
Loosely correlated
-0.42%
More